Description
Lentivirus express a major histocompatibility (pMH) specific T Cell Receptor (recognizing a Epstein-Barr virus), containing no any antibiotic selection. This TCR actives the T-Cells against EB virus infection diseases.
The TCR construct express the antibody specifically recognizes the a Epstein-Barr virus-specific pMH (Ref 1). The TCR α chain variable region with a transmembrane (TM) domain and β chain variable region with a transmembrane (TM) domain, are linked by F2A element, as “(TRαV3/Tm)-F2A-(TRβV5-6/Tm)”
The “target-specific TCRαV and TCRβV sequences” are derived from the verified clones according to published literatures. It also transduces a Puromycin selection gene under the separate RSV promoter, which allow to enrich or select the transduced cells. see the Lentivector scheme below.
About pMH (peptide-major histocompatibility):
TCRs recognize short peptides bound to and presented by class I and II major histocompatibility complex (MHC) molecules on the cell surface. The binding of TCRs to their target pMHC ligands initializes the cell-mediated immune response. The discovery of TCR-pMHC pairs is a challenging task as identifying tumor-specific pMHC ligands. the identification of therapeutically relevant TCR-pMHC will lead to the activation of T cells against infectious diseases and tumors.
see details in Product Manual.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1690
